Allergan Acquires Oculeve for $125,000,000

  • Feed Type
  • Date
  • Company Name
  • Mailing Address
    1082 Pennsylvannia Ave San Francisco, CA 94107 USA
  • Company Description
    Oculeve, Inc. is developing a novel treatment for Dry Eye, a disease affecting many millions of people worldwide. Oculeve was founded in the heart of Silicon Valley by an expert team of scientists, clinicians, engineers and business executives.
  • Website
  • Transaction Type
  • Transaction Amount
  • Transaction Round
  • Proceeds Purposes
  • M&A Terms
    Allergan plc (NYSE: AGN), a leading global pharmaceutical company, and Oculeve, a development-stage medical device company focused on developing novel treatments for dry eye disease, today announced that they have entered into an agreement under which Allergan will acquire Oculeve in an all-cash transaction. Under the terms of the agreement, Allergan will acquire Oculeve for a $125 million upfront payment and commercialization milestone payments related to Oculeve’s lead development program OD-01. The agreement also includes the acquisition of an additional earlier-stage dry eye device development program.

Trending on Xconomy